Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013
(Thomson Reuters ONE) -
Carl Zeiss Meditec AG /
Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six
months of financial year 2012/2013
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Revenue grows to ? 443 million; positive trend for intraocular lenses and in
microsurgery
In the first six months of financial year 2012/2013 medical technology company
Carl Zeiss Meditec increased its revenue by 2.6% compared with the same period
of the previous year, to ? 443 million. Earnings before interest and tax
improved to ? 64.1 million (previous year: ? 61.1 million); the EBIT margin rose
to 14.5% (previous year: 14.1 percent).
JENA, 14 May 2013
Fuelled by persistently dynamic growth in the intraocular lens business and a
continued positive trend in Microsurgery, the Company further increased its
revenue and earnings. As reported in the ad hoc disclosure in April, the first-
quarter revenue deficit in the Ophthalmic Systems business was reduced, although
this took longer than was anticipated at the end of the first quarter.
"Our widespread presence in various business fields and regions enables us to
even out any fluctuations in business and to continue our long-term growth
trend," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "We
are therefore sticking firmly to our innovation strategy, the expansion of our
business in the growth markets and to our overriding objectives."
Revenue by business unit
Once again, the largest revenue contribution in the first half of the year came
from the Microsurgery strategic business unit (SBU). Bolstered by a continued
rise in demand for visualization systems for microsurgery, this SBU achieved
revenue growth of 6% to ? 206.7 million (previous year: ? 195.1 million).
The Ophthalmic Systems SBU was affected by a high level of competition. The
effects of the model change in the area of optical coherence tomography (OCT)
also impacted this SBU. A 4.9% decline in revenue to ? 175.8 million was
countered in the first six months of the year by a positive trend in incoming
orders, which slightly surpasses the previous year's level.
The development of business in the Surgical Ophthalmology SBU was very positive
in the first six months of the year. The double-digit revenue growth (+16.4%) to
? 60.5 million, compared with ? 51.9 million in the same period of the previous
year, is mainly due to very good sales figures in the premium segment for
intraocular lenses for minimally invasive cataract surgery. The picture in terms
of reporting regions was once again quite mixed in the first six months of the
year. Although there were positive impulses from both China and Japan and Latin
America, as well as very good contributions to growth from Germany and Russia,
business was characterized by consumer reticence in the USA and a decline in
Southern Europe. Overall, this resulted in growth of 2.1% in the EMEA region, a
largely stagnating development in the Americas (-0.1%) and a continuation of
robust growth, even after the inclusion of significant currency effects, of
5.9% in the Asia/Pacific region.
Outlook - well equipped for further growth
With consistent expansion of our solutions business, based on a broad product
range and a balanced regional distribution of business, the Company is sticking
firmly to its goals to increase the share of case-number-dependent products and
services to 25% by 2015 and to achieve a total EBIT margin of 15%. Steady growth
is expected for the current financial year. "We anticipate revenue of between
? 880 and 910 million," says Ludwin Monz.
Revenue by strategic business unit
+----------------------+------------------+------------------+-----------------+
|Figures in ? '000 |6 Months 2011/2012|6 Months 2012/2013|Change from |
| | | |previous year |
+----------------------+------------------+------------------+-----------------+
|Ophthalmic Systems |184,781 |175,766 |-4.9% |
+----------------------+------------------+------------------+-----------------+
|Surgical Ophthalmology|51,942 |60,459 |16.4% |
+----------------------+------------------+------------------+-----------------+
|Microsurgery |195,075 |206,732 |6.0% |
+----------------------+------------------+------------------+-----------------+
Revenue by region
+--------------------+------------------+------------------+-------------------+
|Figures in ? '000 |6 Months 2011/2012|6 Months 2012/2013|Change from |
| | | |previous year |
+--------------------+------------------+------------------+-------------------+
|EMEA |149,423 |152,625 |2.1% |
+--------------------+------------------+------------------+-------------------+
|Americas |144,083 |143,875 |-0.1% |
+--------------------+------------------+------------------+-------------------+
|Asia / Pacific |138,292 |146,457 |5.9% |
|region | | | |
+--------------------+------------------+------------------+-------------------+
Press contacts:
Jann Gerrit Ohlendorf, Corporate Communications, Carl Zeiss Meditec AG
Phone+49 3641 220-331, E-Mail: press.meditec(at)zeiss.com
Contact for investors:
Henriette Meyer, Investor Relations, Carl Zeiss Meditec AG
Phone +49 3641 220-106, E-Mail: investors.meditec(at)zeiss.com
www.meditec.zeiss.com/press
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the
German stock exchange, is one of the world's leading medical technology
companies. The company supplies innovative technologies and application-oriented
solutions designed to help doctors improve the quality of life of their
patients. It provides complete packages of solutions for the diagnosis and
treatment of eye diseases, including implants and consumable materials. The
company creates innovative visualization solutions in the field of microsurgery.
The medical technology portfolio of Carl Zeiss Meditec is rounded off by
promising, future-oriented technologies such as intraoperative radiotherapy. In
financial year 2011/2012 (ended 30 September) the Group's more than 2,400
employees generated revenue of almost ? 862 million. The head office of Carl
Zeiss Meditec is in Jena, Germany.
The company has subsidiaries in Germany and abroad; more than 50 percent of its
employees are based in the USA, Japan, Spain and France. The Center for Research
and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations
Center for Research and Development in Shanghai, China, strengthen the Company's
presence in these rapidly developing economies. Around 35 percent of Carl Zeiss
Meditec shares are in free float. The remaining approx. 65 percent are held by
Carl Zeiss AG, one of the world's leading groups in the optical and
optoelectronic industries.
Fore more than 160 years Carl Zeiss has been contributing to the progress of
technology on the markets for Industrial Solutions, Research Solutions, Medical
Technology and Consumer Optics, improving the quality of life for many people.
Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.
For more information visit our website at: www.meditec.zeiss.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Carl Zeiss Meditec AG via Thomson Reuters ONE
[HUG#1701455]
Unternehmensinformation / Kurzprofil:
Datum: 14.05.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 259450
Anzahl Zeichen: 8922
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 150 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
